Active Shortage Injection Oncology
Azacitidine Injection · 2,093 days since initial FDA posting
Brand: VIDAZA
FDA lists Azacitidine Injection as Active Shortage (Bristol Myers Squibb Co.).
Availability on file: Available
Azacitidine Injection: Active Shortage
Available Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Azacitidine Injection
- Manufacturer
- Bristol Myers Squibb Co.
- Dosage Form
- Injection
- Presentation
- Vidaza, Injection, 100 mg (NDC 59572-102-01)
- Package NDC
- 59572-102-01
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Dec 18, 2020
- Last Updated
- Mar 17, 2026
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Nearby, Other Azacitidine Shortage Records
Azacitidine Injection
Meitheal Pharmaceuticals, Inc.
Injection
Azacitidine Injection
Eugia US LLC
Injection
Azacitidine Injection
Fresenius Kabi USA, LLC
Injection
Azacitidine Injection
Accord Healthcare Inc.
Injection
Azacitidine Injection
Dr. Reddy's Laboratories, Inc.
Injection
Azacitidine Injection
Teva Pharmaceuticals USA, Inc.
Injection